Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.
Antibodies, Monoclonal, Humanized
/ adverse effects
Conjunctivitis
/ drug therapy
Consensus
Dermatitis, Atopic
/ complications
Dermatologic Agents
/ adverse effects
Humans
Ointments
/ therapeutic use
Ophthalmic Solutions
/ therapeutic use
Patient Education as Topic
Referral and Consultation
Surveys and Questionnaires
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
21
01
2019
accepted:
07
03
2019
pubmed:
6
5
2019
medline:
16
1
2020
entrez:
7
5
2019
Statut:
ppublish
Résumé
Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab. To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Council (IEC). Electronic survey and in-person discussion of management strategies. Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupilumab treatment should be continued when possible, with appropriate referral to an ophthalmologist. The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupilumab access were not excluded from the survey. The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during treatment with dupilumab.
Sections du résumé
BACKGROUND
BACKGROUND
Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab.
OBJECTIVE
OBJECTIVE
To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Council (IEC).
METHODS
METHODS
Electronic survey and in-person discussion of management strategies.
RESULTS
RESULTS
Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupilumab treatment should be continued when possible, with appropriate referral to an ophthalmologist.
LIMITATIONS
CONCLUSIONS
The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupilumab access were not excluded from the survey.
CONCLUSION
CONCLUSIONS
The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during treatment with dupilumab.
Identifiants
pubmed: 31056788
doi: 10.1111/jdv.15608
pmc: PMC6619239
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Dermatologic Agents
0
Ointments
0
Ophthalmic Solutions
0
dupilumab
420K487FSG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1224-1231Informations de copyright
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Ophthalmology. 2003 Mar;110(3):487-92
pubmed: 12623809
J Ocul Pharmacol Ther. 2009 Aug;25(4):365-72
pubmed: 19441889
Am Fam Physician. 2010 Jan 15;81(2):137-44
pubmed: 20082509
Curr Opin Allergy Clin Immunol. 2010 Oct;10(5):478-85
pubmed: 20720488
J Am Acad Dermatol. 2014 Feb;70(2):338-51
pubmed: 24290431
J Am Acad Dermatol. 2014 Mar;70(3):569-75
pubmed: 24342754
Br J Ophthalmol. 2014 Aug;98(8):1023-7
pubmed: 24695688
J Am Acad Dermatol. 2014 Aug;71(2):327-49
pubmed: 24813298
J Am Acad Dermatol. 2014 Jul;71(1):116-32
pubmed: 24813302
J Am Acad Dermatol. 2014 Dec;71(6):1218-33
pubmed: 25264237
J Eur Acad Dermatol Venereol. 2016 May;30(5):729-47
pubmed: 27004560
Pediatr Dermatol. 2016 Jul;33(4):388-98
pubmed: 27273433
N Engl J Med. 2016 Dec 15;375(24):2335-2348
pubmed: 27690741
N Engl J Med. ;376(11):1090
pubmed: 28301105
Lancet. 2017 Jun 10;389(10086):2287-2303
pubmed: 28478972
J Am Acad Dermatol. 2017 Aug;77(2):280-286.e1
pubmed: 28601391
Allergy. 2017 Dec;72(12):2026-2030
pubmed: 28605026
Br J Dermatol. 2018 Mar;178(3):768-775
pubmed: 28865094
Br J Dermatol. 2018 May;178(5):1083-1101
pubmed: 29193016
Br J Dermatol. 2018 May;178(5):1220
pubmed: 29333603
J Am Acad Dermatol. 2018 May;78(5):863-871.e11
pubmed: 29353026
J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1778-1780.e1
pubmed: 29432961
J Eur Acad Dermatol Venereol. 2018 May;32(5):657-682
pubmed: 29676534
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
J Eur Acad Dermatol Venereol. 2018 Jun;32(6):850-878
pubmed: 29878606
J Allergy Clin Immunol. 2019 Jan;143(1):135-141
pubmed: 29906525
JAMA Dermatol. 2018 Oct 1;154(10):1208-1211
pubmed: 30167653
Br J Dermatol. 2019 May;180(5):1248-1249
pubmed: 30597515
Ophthalmologica. 1980;180(3):129-32
pubmed: 7454225